US-based healthcare company Merck invested $35m in the Merck Lumira Biosciences Fund yesterday, taking it to $43m raised.
The fund is targeting a $50m final closing. The fund was set up by a Merck subsidiary in collaboration with venture firm Lumira Capital, and fund of funds Teralys Capital, which is also investing in the fund, and other unnamed partners, to invest in early stage life science innovation in Québec [pictured].
Cyril Schiever, president and managing director of Merck…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
